COVID-19 Impact on Behaviors across the 24-Hour Day in Children and Adolescents: Physical Activity, Sedentary Behavior, and SleepCommentary Published on 2020-09-162022-10-31 Journal: Children [Category] COVID-19, [키워드] 24-h day activity adolescents Behavior children COVID-19 COVID-19 pandemic Day Health Impact increases in physical activity preliminary evidence recommendation Sedentary behavior significant decrease Sleep Spread virus [DOI] 10.3390/children7090138 PMC 바로가기 [Article Type] Commentary
Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-09-092022-10-29 Journal: Trials [Category] Coronavirus, SARS, [키워드] 24 hour 7-point ordinal scale absence addition administration Admission ALT anticipated assigned AST baseline biological parameters candidate Care clinical Clinical research clinical status clinical trial clinician Comorbidity conditions Control control arm control group Coronavirus infections Council COVID 19 COVID-19 COVID-19 infection criteria current D-dimer Day death rate decrease discharge dissemination dose drug Duration early stage Efficacy element ELISA enrolment EudraCT European evaluate exclusion criteria exploratory extracorporeal membrane oxygenation Frame harmonization hospitalisation hospitalised hospitalised patient hyperinflammatory status hypersensitivity Hypothesis identify IL-6 IL-6 levels IL-6 receptor inhibitors IL-6R In-hospital incidence Inclusion inclusion criteria independent Infection Informed inhibitor interstitial pneumonia Intervention intervention group intestinal perforation Invasive mechanical ventilation investigator investigator-initiated lactation Local marker measure mechanical ventilation moderate moderate-severe neutrophil count Non-invasive non-invasive ventilation number number of death objective Open label trial outbreak outcome oxygen Oxygenation pandemic participant pathogen patients treated performed Platelet Pneumonia positive positive RT-PCR Positive test Prednisone Presence Prevent progression protocol random randomisation randomised randomised controlled trial receive recruited recruitment Registered reported requiring supplemental oxygen responsible routine clinical practice RT-PCR SAEs Sample size sarilumab SARS-CoV-2 SARS-COV-2 infection score Sepsis Serious Adverse Event serum Severe COVID-19 Infection single center single dose Spain Standard Standard of care status Study protocol Subcutaneous subcutaneous injection the patient therapy treated Treatment treatment arm treatment with tocilizumab Trial ULN union unit verbal website [DOI] 10.1186/s13063-020-04588-5 PMC 바로가기 [Article Type] Letter
Disease progression patterns and risk factors associated with mortality in deceased patients with COVID‐19 in Hubei Province, ChinaOriginal Research Published on 2020-08-282022-10-30 Journal: Immunity, Inflammation and Disease [Category] COVID-19, MERS, SARS, [키워드] Acute cardiac injury Acute kidney injury acute respiratory distress age analyzed assessment Chest computed tomography China collected Complication coronavirus disease COVID‐19 COVID‐19 patient COVID‐19 patients COVID‐19 Critical Day death Deceased description Deterioration died disease course Disease progression disease progression pattern dysfunction enrolled Factor failure Hospitalization hospitals illness onset independent risk factor initial Laboratory laboratory data material Mortality objective Patient patients preexisting comorbidities preexisting comorbidity progression radiological Result risk factor SARS‐CoV‐2 Sepsis SOFA SOFA score survived surviving patient surviving patients syndrome variables [DOI] 10.1002/iid3.343 PMC 바로가기 [Article Type] Original Research
An epidemiological model to aid decision-making for COVID-19 control in Sri LankaResearch Article Published on 2020-08-272022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, SARS, [키워드] 95% CI average country COVID-19 Day diagnosed doubling epidemiological Government Health health system ICU increase Infection limit Local lockdown lockdown restrictions parameter public health measures recovered resources Result saturated suggested Transmission [DOI] 10.1371/journal.pone.0238340 PMC 바로가기 [Article Type] Research Article
The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial인공호흡기를 사용하는 COVID-19 환자에서 위약과 비교하여 72시간 동안 1ng/kg/min 용량의 프로스타사이클린(일로프로스트) 주입 효과: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-08-262022-08-13 Journal: Trials [Category] MERS, 임상, [키워드] (Iloprost (normal saline) 1:1 Acute coronary syndrome Adult patient Adult patients age anticipated Biomarker bleeding blinded Blinding block can not Capital Capital Region capture Clinicians comparator concealed conducted Confirmed Confirmed COVID-19 infection Consent coronary syndrome COVID-19 COVID-19 infection COVID-19 patients criteria Day defined Denmark dissemination dose element endothelial endotheliopathy EudraCT exclusion criteria exploratory facilitate FIVE heart failure Hvidovre Hospital hypersensitivity Iloprost intensive care unit intensive care units investigators Local mechanical ventilation mechanically ventilated mechanically ventilated COVID-19 patients mechanically ventilated patient multicenter normal saline number objective outcome parallel group participant Patient patients performed Placebo Pregnancy primary endpoint prostacyclin protocol randomisation randomised Randomized Randomized controlled trial recruitment REDCap Region Sample size sequence statisticians status stratified Study protocol Suspected thrombomodulin total sample size Trial Urine website Withdrawal [DOI] 10.1186/s13063-020-04696-2 PMC 바로가기 [Article Type] Letter
Persistent SARS-COV-2 RNA positivity in a patient for 92 days after disease onset A case report4900 Published on 2020-08-212022-10-30 Journal: Medicine [Category] COVID-19, MERS, [키워드] anal swabs antiviral drug antiviral therapy Case report Cell clinical recovery clinical symptom collected coronavirus disease Coronavirus infection COVID-19 Day determine discharged disease onset effective Follow-up Hospitalization knowledge measure Mild symptom no symptom nucleic acid nucleic acid test nucleic acids observation occurred Patient patients patients with COVID-19 persistent physical Pneumonia positive positive result provided quarantine regimen required Research resolved RNA SARS-CoV-2 SARS-CoV-2 nucleic acid SARS-CoV-2 nucleic acids shown tested the patient the SARS-CoV-2 Transmission viral infection [DOI] 10.1097/MD.0000000000021865 PMC 바로가기 [Article Type] 4900
Establishing a 130-Bed Field Intensive Care Unit to Prepare for COVID-19 in 7 Days in Bahrain Military HospitalConcepts in Disaster Medicine Published on 2020-08-122022-10-31 Journal: Disaster Medicine and Public Health Preparedness [Category] COVID-19, MERS, [키워드] Bahrain coronavirus disease COVID-19 COVID-19 patient Critical care Day Establishing field field-ICU functional hospital ICU implementation intensive care intensive care unit isolation facility Kingdom National outbreak Patient treat [DOI] 10.1017/dmp.2020.297 PMC 바로가기 [Article Type] Concepts in Disaster Medicine
Change in five-factor model personality traits during the acute phase of the coronavirus pandemicResearch Article Published on 2020-08-062022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, SARS, [키워드] acute phase Anxiety change changed changes in conscientiousness coronavirus COVID-19 Day distress Evidence Factor hypotheses Interpretation Model Neuroticism outbreak pandemic participant Psychological reflected sick slow Spread tested The United States [DOI] 10.1371/journal.pone.0237056 PMC 바로가기 [Article Type] Research Article
muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial코비드-19-실험 약물 및 기전(TACTIC-E)으로 입원한 ICu 전 환자에 대한 다중 암 치료 연구: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-07-312022-08-13 Journal: Trials [Category] SARS, 임상, [키워드] able to swallow adaptive Adaptive trial added Admission age Ambrisentan Analysis approved Arm ARMS balloon pump balloon pump) baseline benefit Biomarker blinded Blinding calculated Cambridge Cambridge University Hospitals NHS Foundation Trust can not cardiac cardiovascular complications cells clearance clinical endpoint Clinical endpoints clinical picture clinically Combination comparator comparison Complete Composite Course COVID-19 COVID-19 infection creatinine creatinine clearance CRP Dapagliflozin Data analysis Day death defined demonstrated determine diabetes Diagnosis discretion disease dissemination drug drugs ECMO EDP1815 Efficacy element enrolled envelope EU Clinical Trial EU Clinical Trials EudraCT Evidence evidence of exclusion criteria Experimental drugs failure feature fixed foundation Gault Gender group hypertension immunomodulation immunomodulatory incidence include Inclusion independent independent data monitoring committee Inotropes Intervention Invasive mechanical ventilation investigator Laboratory late stage male mechanism membrane neutrophil Neutrophils NHS number objective Occurrence on admission once daily Open-label open-label trial opinion option Organ failure organ support Other outcome Oxygenation pandemic Parallel Arm participant Patient patients with COVID-19 performed phase platform Platform trial positive positive COVID-19 predicted Primary outcome principal investigator progression protocol Radiographic radiological randomisation randomised Randomized controlled trial recruited reduce Registered related disease renal renal failure risk Sample size severity Standard of care status stratified Study protocol subject Support tablets the patient therapy Treatment treatment arm Trial Trial registration triggered Trust university website [DOI] 10.1186/s13063-020-04618-2 PMC 바로가기 [Article Type] Letter
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trialACCORD: 입원 환자의 COVID-19 치료를 위한 여러 후보 약제의 효능과 안전성을 평가하기 위한 다기관, 원활한, 2상 적응형 무작위화 플랫폼 연구: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-07-312022-08-13 Journal: Trials [Category] SARS, 임상, [키워드] 1:1 a BTK inhibitor Acalabrutinib adaptive added adjusted agent Amendment analyses Analysis Anti-viral approval Arm baseline bemcentinib Blinding block BTK inhibitor candidate Candidates cause caused changed clinical Clinical characteristics Clinical improvement clinically comparator complement COVID COVID-19 current Day discharge disease dissemination dropped Efficacy element Endpoint England estimation EudraCT evaluate Evidence evidence of experimental arm GRADE group help heparin hospital hospitalised include Inflammatory response inhibitor Ireland IRT Mask Master protocol Mild Mild disease monoclonal antibody Multiple nasal prongs National non-invasive ventilation number objective open open label Ordinal Scale outcome oxygen Oxygen therapy oxygen therapy) participant Patient performed Phase 2 phase II platform proceed protocol protocols provide randomisation randomised randomised controlled randomised controlled trial randomization recruited recruitment reduce Registered Regulatory reported Respiratory failure response response rate Safety Sample size SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 spike protein seamless selected severity shown SOC Spike protein Stage stage 2 stages Standard of care status stratified Study protocol sustained Task Force technology the spike protein the WHO therapy time treat Treatment treatment of COVID-19 Trial Trial registration Viral viral infection virus website with COVID-19 working zilucoplan [DOI] 10.1186/s13063-020-04584-9 PMC 바로가기 [Article Type] Letter